THE USE OF FORMEN COMBI IN PROSTATE ADENOMA IN MEN OF CHILDBEARING AGE.
Keywords:
Formen combi, serenoa repens, tamsulosin, erectile dysfunction, benign prostatic hyperplasia, symptoms of the lower urinary tract.Abstract
To analyze the effect of Formen combi at a dose of 160 mg twice a day on sexual function compared to tamsulosin at a dose of 0.4 mg once, in men with lower urinary tract symptoms (LUTs) complicated by benign prostatic hyperplasia.
Downloads
References
Madersbachera S., Alivizatosb G., Nordlingc J. et al. EAU 2004 Guidelines on Assessment, Therapy and Follow-Up of Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction (BPH Guidelines). European Urology. 2004; 46:547–554. DOI: 10.1016/j.eururo.2004.07.016.
McVary K.T. A review of combination therapy in patients with benign prostatic hyperplasia. Clin Ther. 2007;29(3):387–398. DOI: 10.1016/S0149-2918(07)80077-4.
Van Dijk M.M., de la Rosette J.J., Michel M.C. Effects of alpha — adrenoceptor antagonists on male sexual function. Drugs, 2006;66:287–301. DOI: 10.2165/00003495–200666030–00002.
McConnell J.D., Roehrborn C.G., Bautista O.M. et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349: 2387–2398. DOI: 10.1056/NEJMoa030656.
Roehrborn C.G., Siami P., Barkin J. et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123–131. DOI: 10.1016/j.eururo.2009.09.035.
Hammarsten J., Peeker R. Urological aspects of the metabolic syndrome. Nat Rev Urol. 2011;8(9):483–494. DOI: 10.1038/nrurol.2011.112.
Hennenberg M., Stief C.G., Gratzke C. Prostatic α1-adrenoceptors: new concepts of function, regulation, and intracellular signaling. Neurourol Urodyn. 2014;33(7):1074–1085. DOI: 10.1002/nau.22467.
Kamalov A. A., Takhirzade A.M. Approaches to drug treatment of patients with a high risk of progression of benign prostatic hyperplasia depending on concomitant erectile dysfunction. Urology. 2018;3:70–77. DOI: 10.18565/urology.2018.3.70-77.
Bartram W. European Union herbal monograph on Serenoa repens. European Medicines Agency; 2016.
Oelke M., Bachmann A., Descazeaud A. et al. EAU guidelines on the management of male lower urinary tract symptoms, including benign prostatic obstruction. EAU guidelines; 2013.
De la Taille A. Therapeutic Approach: The Importance of Controlling Prostatic Inflammation. European Urology Supplements. 2013;12:116–122. DOI: 10.1016/j.eursup.2013.08.003.
Vacherot F., Azzouz M., Gil-Diez-De-Medina S., Colombel M., De LaTaille A., Lefrere Belda M.-A., et al. (2000) Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon®) in benign prostatic hyperplasia. Prostate 45: 259–259.
Di Silverio F., Monti S., Sciarra A., Varasano P.A., Martini C., Lanzara S., et al. (1998) Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 37: 77–83.
Giuliano F. (2006) Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int 97: 34–38.
Zlotta A.R., Teillac P., Raynaud J.P., Schulman C.C. (2005) Evaluation of male sexual function in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), tamsulosin or finasteride. Eur Urol 48: 269–276.
Debruyne F., Boyle P., Calais Da Silva F., Gillenwater J.G., Hamdy F.C., Perrin P., et al. (2004a) Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients – PERMAL study subset analysis. Eur Urol 45: 773–779.
Carraro J.C., Raynaud J.P., Koch G., Chisholm G.D., Di Silverio F., Teillac P., et al. (1996) Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 29: 231–240.
Oelke, M., Bachmann, A., Descazeaud, A., Emberton, M., Gravas, S., Michel, M.C. et al. (2011) Guidelines on the treatment of non-neurogenic male LUTS. EAU online Guidelines.
Suzuki M., Ito Y., Fujino T. et al. Pharmacological effects of saw palmetto extract in the lower urinary tract. Acta Pharmacol Sin. 2009;30 (3):271–281. DOI: 10.1038/aps.2009.1.
Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis. Debruyne F, Boyle P, Calais Da Silva F, Gillenwater JG, Hamdy FC, Perrin P, Teillac P, Vela-Navarrete R, Raynaud JP, Schulman CC.
Eur Urol. 2004 Jun; 45(6):773-9; disucssion 779-80.
Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Gerber GS, Kuznetsov D, Johnson BC, Burstein JD. Urology. 2001 Dec; 58(6):960-4; discussion 964-5.
Long-term efficacy of Serenoa repens treatment in patients with mild and moderate symptomatic benign prostatic hyperplasia. Sinescu I, Geavlete P, Multescu R, Gangu C, Miclea F, Coman I, Ioiart I, Ambert V, Constantin T, Petrut B, Feciche BUrol Int. 2011; 86(3):284-9.
